Skip to content

Multi-omics study of diabetic nephropathy

Multi-omics study of diabetic nephropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093494
Enrollment
Unknown
Registered
2024-12-05
Start date
2022-09-01
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DKD

Interventions

healthy controls:None
diabetic patients:None

Sponsors

The First Affiliated Hospital of Henan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for healthy people: (1) No age or gender restrictions; (2) No family genetic diseases or infectious diseases; (3) No obvious diseases and qualified physical examination (all examination items such as renal function, blood lipids, liver function and glucose and other basic indicators are within the normal range, physical signs are complete and without obvious abnormalities); (4) Good compliance and cooperation with various examinations; (5) Voluntary participation in clinical research and signing of informed consent. 2. Inclusion criteria for diabetic patients: (1) Meet the diagnostic criteria for diabetes; (2) Sober, without obvious mental abnormalities, and can undergo medical history interviews; (3) Complete records of symptoms and examinations without any omissions; (4) Good compliance and cooperation with various examinations; (5) Voluntary participation in clinical research and signed informed consent. 3. Inclusion criteria for patients with diabetic nephropathy: (1) Those who meet the criteria for early diabetic nephropathy; (2) Regardless of age or gender; (3) Renal function indicators such as serum creatinine (SCr) that remain stable below 265umol/L for 3 months and glomerular filtration rate (GFR) that remain stable above 40ml/min; (4) Those whose diastolic blood pressure is stable below 90mmHg after antihypertensive treatment, whose blood sugar is basically controlled, and whose glycosylated hemoglobin is controlled below 7%; (5) Those who have given informed consent and are willing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria for healthy controls: Patients who have any of the following conditions cannot be selected for this study: (1) Women who are pregnant, breastfeeding, or may become pregnant; (2) Patients who have been diagnosed with various serious diseases. Such as malignant tumors, severe infections, liver and kidney dysfunction, acute cerebrovascular disease, and coronary heart disease; (3) Those with obvious abnormalities in hospital physical examinations, such as heart and lung auscultation, X-rays, electrocardiograms, B-ultrasound, laboratory blood biochemical tests (blood sugar, blood lipids, liver function), female gynecological special examinations, etc.; (4) Those who have participated in other clinical trials in the past 3 months; (5) Those who are considered by the researchers to be unsuitable for participating in this project. 2. Exclusion criteria for diabetic patients: (1) Non-diabetic patients or diabetic emergency patients with other critical diseases who need emergency treatment; (2) Patients with mental illness, irrelevant answers, and inability to accurately diagnose; (3) Patients with diabetic critical illness within the past month, such as ketoacidosis, diabetic hyperosmolar state, and severe infection; (4) Patients who have been clearly diagnosed with various serious diseases, such as malignant tumors, severe infections, liver and kidney dysfunction, acute cerebrovascular disease, and coronary heart disease; (5) Other conditions that the researchers believe are not suitable for participating in this project. 3. Exclusion criteria for diabetic nephropathy: (1) Patients with refractory edema; (2) Urine protein greater than 10g/24hr and serum albumin less than 2.5g/L; (3) Patients with renal vascular hypertension; (4) Pregnant or lactating women; (5) Patients with acute complications of diabetes (including diabetic hyperosmolar coma, diabetic ketonemia and ketoacidosis, diabetic lactic acidosis, and acute diabetic infection); (6) Patients who have been diagnosed with various serious diseases, such as malignant tumors, severe infections, liver and kidney dysfunction, acute cerebrovascular disease, and coronary heart disease.

Design outcomes

Primary

MeasureTime frame
Urine protein ;Creatinine;

Countries

China

Contacts

Public ContactHongwei Jiang

The First Affiliated Hospital of Henan University of Science and Technology

jianghw@haust.edu.cn+86 136 5388 0139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026